Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 277

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study

Open access
Hsu, Chiun, Tsou, Hsiao-Hui, Lin, Shyh-Jer, Wang, Ming-Chung, Yao, Ming, Hwang, Wen-Li, Kao, Woei-Yau, Chiu, Chang-Fang, Lin, Sheng-Fung, Lin, Johnson, Chang, Cheng-Shyong, Tien, Hwei-Fang, Liu, Tsang-Wu, Chen, Pei-Jer, Cheng, Ann-Lii·2014·Hepatology

Abstract

Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with “resolved” HBV infection (hepatitis B surface antigen [HBsAg] negative and hepatitis B core antibody [anti-HBc] positive) can occur, but the true incidence and severity remain unclear. From June 2009 to December 2011, 150 newly diagnosed lymphoma patients with resolved HBV infection who were to receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy were prospectively followed. HBV DNA was checked at baseline, at the start of each cycle of chemotherapy, and every 4 weeks for 1 year after completion of rituximab-CHOP chemotherapy. Patients with documented HBV reactivation were treated with entecavir at a dosage of 0.5 mg/day for 48 weeks. HBV reactivation was defined as a greater than 10-fold increase in HBV DNA, compared with previous nadir levels, and hepatitis flare was defined as a greater than 3-fold increase in alanine aminotransferase (ALT) that exceeded 100 IU/L. Incidence of HBV reactivation and HBV-related hepatitis flares was 10.4 and 6.4 per 100 person-year, respectively. Severe HBV-related hepatitis (ALT >10-fold of upper limit of normal) occurred in 4 patients, despite entecavir treatment. Patients with hepatitis flare exhibited significantly higher incidence of reappearance of HBsAg after HBV reactivation (100% vs. 28.5%; P = 0.003). Conclusion: In lymphoma patients with resolved HBV infections, chemotherapy-induced HBV reactivation is not uncommon, but can be managed with regular monitoring of HBV DNA and prompt antiviral therapy. Serological breakthrough (i.e., reappearance of HBsAg) is the most important predictor of HBV-related hepatitis flare. (Hepatology 2014;59:2092–2100)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.26718

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 277

Metadata

Authors
Hsu, C., Tsou, H.-H., Lin, S.-J., Wang, M.-C., Yao, M., Hwang, W.-L., Kao, W.-Y., Chiu, C.-F., Lin, S.-F., Lin, J., Chang, C.-S., Tien, H.-F., Liu, T.-W., Chen, P.-J., & Cheng, A.-L.
Venue
Hepatology
Published
2014-06
Volume
59
Issue
6
Pages
2092-2100
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1979792611
Cited by
277
References
19
FWCI
20.54
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. https://app.cochat.ai/papers/10.1002/hep.26718
The paper
Hsu, C., Tsou, H.-H., Lin, S.-J., Wang, M.-C., Yao, M., Hwang, W.-L., Kao, W.-Y., Chiu, C.-F., Lin, S.-F., Lin, J., Chang, C.-S., Tien, H.-F., Liu, T.-W., Chen, P.-J., & Cheng, A.-L. (2014). Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology. https://doi.org/10.1002/hep.26718

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.